Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis

Ricardo D. Parrondo; Keren Sam; Ahsan Rasheed; Victoria Alegria; Taimur Sher; Vivek Roy; Asher Chanan-Khan; Sikander Ailawadhi

doi:10.1038/s41408-022-00662-0

Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis

Ricardo D. Parrondo, Keren Sam, Ahsan Rasheed, Victoria Alegria, Taimur Sher, Vivek Roy, Asher Chanan-Khan, Sikander Ailawadhi

Hematology / Oncology / Cancer Center / Breast Clinic

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Article number	66
Journal	Blood cancer journal
Volume	12
Issue number	4
DOIs	https://doi.org/10.1038/s41408-022-00662-0
State	Published - Apr 2022

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1038/s41408-022-00662-0

Cite this

@article{72a20ad1238b4b13967b3f531ed49686,

title = "Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis",

author = "Parrondo, {Ricardo D.} and Keren Sam and Ahsan Rasheed and Victoria Alegria and Taimur Sher and Vivek Roy and Asher Chanan-Khan and Sikander Ailawadhi",

note = "Funding Information: RDP, VA, VR, TS, and AC-K declare no competing interests. SA receives honoraria from Celgene and Takeda as well as research funding from Amgen, Janssen, Pharmacyclics, Cellectar, Bristol Myers Squibb, Medimmune, and Phosplatin. ",

year = "2022",

month = apr,

doi = "10.1038/s41408-022-00662-0",

language = "English (US)",

volume = "12",

journal = "Blood cancer journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma

T2 - A single center analysis

AU - Parrondo, Ricardo D.

AU - Sam, Keren

AU - Rasheed, Ahsan

AU - Alegria, Victoria

AU - Sher, Taimur

AU - Roy, Vivek

AU - Chanan-Khan, Asher

AU - Ailawadhi, Sikander

N1 - Funding Information: RDP, VA, VR, TS, and AC-K declare no competing interests. SA receives honoraria from Celgene and Takeda as well as research funding from Amgen, Janssen, Pharmacyclics, Cellectar, Bristol Myers Squibb, Medimmune, and Phosplatin.

PY - 2022/4

Y1 - 2022/4

UR - http://www.scopus.com/inward/record.url?scp=85128362259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85128362259&partnerID=8YFLogxK

U2 - 10.1038/s41408-022-00662-0

DO - 10.1038/s41408-022-00662-0

M3 - Letter

C2 - 35440072

AN - SCOPUS:85128362259

SN - 2044-5385

VL - 12

JO - Blood cancer journal

JF - Blood cancer journal

IS - 4

M1 - 66

ER -

Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this